Press Releases

March 30 2016

Washington, D.C. (March 30, 2016) – Biotechnology Innovation Organization (BIO) President...

March 9 2016

BIO Executive Vice President for Health Policy Dan Durham released the following statement...

February 26 2016

Washington, D.C. (February 26, 2016) – The Biotechnology...

February 24 2016

“BIO extends our congratulations to Dr. Califf on his confirmation as Commissioner of the...

February 11 2016

Former HHS Secretary Donna Shalala will also testify

February 8 2016

Ad Launches Campaign Spotlighting Benefits and Value of Medical Breakthroughs

February 3 2016

Innovative biopharmaceutical industry focused on value, advocating for needed reforms...

January 21 2016

Washington, D.C. (January 21, 2016) – The Biotechnology...

January 21 2016

BVGH engages leading biopharmaceutical companies in partnerships and programs to address...

January 21 2016

Proposed legislation will accelerate medical innovation

December 16 2015

BIO today welcomed legislation to extend critical tax incentives that are important to...

December 8 2015

BIO and Parent Project Muscular Dystrophy (PPMD) announce the launch of a new initiative...

December 1 2015

Bill would extend a cost-saving JOBS Act provision

November 18 2015

BIO released a list of seven proposed topics for the November 20th U.S. Department of...

October 8 2015

Communication Important for Patients and Physicians

September 22 2015

“The proposal released today by the Clinton campaign would do irreparable harm to the...

June 17 2015

Important Legislation Helps More Than 30 Million Americans Suffering From Rare Diseases...

May 21 2015

Biotechnology Industry Organization praises the Energy and Commerce Committee for approving...

May 1 2015

BIO supports transparency in sharing data in the life sciences industry so that patients and...

April 30 2015

Enhancing the capital formation ecosystem will help expedite the next generation of...

February 25 2015

Washington, D.C. (February 25, 2015) – The Biotechnology Industry...

January 27 2015

BIO releases the following statement on the 21st Century Cures Initiative discussion draft...

January 23 2015

The Biotechnology Industry Organization (BIO) issued the following statement in response to...

January 7 2015

Biosimilars raise novel and complex questions of science and law ...

December 5 2014

BIO applauds the unanimous House passage late Wednesday of the Adding Ebola to the FDA...

November 18 2014

Washington, D.C. (November 18, 2014) – BIO issued the following statement in response to...

October 1 2014

Relationships between life sciences industry and physicians lead to stronger R&D...

September 22 2014

Washington, D.C. (September 22, 2014) – BIO President and CEO James Greenwood joined...

April 7 2014

The EXPIRE Act would extend tax credits that expired at the end of 2013, including...

March 25 2014

The Biotechnology Industry Organization (BIO) and the Indiana Health Industry Forum (IHIF)...

March 5 2014

Many of the provisions included in this budget proposal would jeopardize the continued biotech...

January 30 2014

Patients Should Be Informed if Doctor's Prescription Changed

January 14 2014

Spending plan would enable the FDA to access $85 million in sequestered user fees

January 13 2014

BIO expresses strong support for the “Bipartisan Congressional Trade Priorities Act of...

January 9 2014

Nature Biotechnology published ...

November 18 2013

BIO commends the Senate for approving H.R. 3204, the Drug Quality and Security Act.

November 6 2013

Bill will encourage investment in growing innovative companies

August 21 2013

BIO applauds Rep. Michael Burgess (R-TX) and Rep. Jackie Speier (D-CA) for introducing the...

August 1 2013

S. 1413 and H.R. 2725 would exempt future FDA user fees from sequestration.

July 10 2013

H.R. 2629 will cut compliance costs for innovative emerging biotech companies

May 24 2013

Rx Response elevates to Alert status to address potential impact from Moore tornado on supply...

February 28 2013

BIO lauds the Senate for passing H.R. 307, the Pandemic and All-Hazards Preparedness...

January 25 2013

Bill will accelerate R&D to help support nation’s preparedness against chemical,...

October 1 2012

Pharmaceutical Research and Manufacturers of America PhRMA President and CEO John J....

July 23 2012

Groups issue booklet to help biotechnology and pharmaceutical companies identify pipeline...

June 28 2012

Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood issued the...

June 27 2012

Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood released the...

May 24 2012

BIO commends the bipartisan Senate approval of FDASIA, which includes a reauthorization of the...

May 24 2012

BIO applauds Senator Robert Menendez for introducing the “The Extension of the Therapeutic...

April 24 2012

The Biotechnology Industry Organization (BIO) announced today its selection of Senator Michael...

April 24 2012

The Biotechnology Industry Organization (BIO) announced today its selection of Representative...

April 24 2012

The Biotechnology Industry Organization (BIO) announced today its selection of Senator Kay...

April 24 2012

The Biotechnology Industry Organization (BIO) announced today its selection of Representative...

April 24 2012

The Biotechnology Industry Organization (BIO) announced today its selection of Senator Robert...

April 24 2012

The Biotechnology Industry Organization (BIO) announced today its selection of Representative...

April 17 2012

The Biotechnology Industry Organization (BIO) submitted comments yesterday to the U.S. Food...

March 28 2012

H.R. 4274 will encourage continued investment in pediatric research.

March 6 2012

The FAST Act will modernize the Accelerated Approval pathway to expedite the...

February 15 2012

The bill will modernize the FDA and accelerate patient access to cures and new treatments.

February 14 2012

“The biotechnology industry has long been an engine for economic development and job...

February 9 2012

BIO President and CEO Jim Greenwood issued the following statement regarding the newly...

January 12 2012

Biotechnology Industry Organization (BIO) announces programming for 2012 event, to be held in...

November 15 2011

Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood issued the following...

September 20 2011

Elaine Chao will provide a keynote address at the upcoming inaugural BIO China International...

September 1 2011

Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood released the...

July 27 2011

BIO praised today’s ruling by a U.S. District Court dismissing a lawsuit that sought to...

June 28 2011

BIO announced its endorsement of the “Joint Declaration on Cooperation in the Fight...

June 15 2011

High-level members of the Obama Administration will gather with leaders from the...

May 25 2011

BIO commends Reps. Davis (D-Ca) and Schwartz (D-PA) for their continued efforts to extend the...

May 4 2011

BIO announces selection of Congressman Fred Upton (R-MI) as Legislator of the Year for 2010 -...

May 4 2011

BIO announced today its selection of Senator Bob Casey (D-PA) as Legislator of the Year for...

May 4 2011

BIO announces its selection of Representative David E. Price (D-NC) as Legislator of the Year...

May 4 2011

BIO announces its selection of Michael Capuano (D-MA) as Legislator of the Year for 2010 -...

May 4 2011

The Biotechnology Industry Organization (BIO) announced today its selection of Representative...

May 4 2011

The Biotechnology Industry Organization (BIO) announced today its selection of Congressman...

May 3 2011

BIO along with the Juvenile Diabetes Research Foundation (JDRF) will feature a two-day...

April 19 2011

BIO announces that Dr. Jörg Reinhardt, CEO of Bayer HealthCare, will provide the keynote...

April 19 2011

Democratic and Republican party leaders and strategists will share their differing...

March 16 2011

NIH Director Francis Collins, MD, PhD will share his insights on how ground-breaking biotech...

February 22 2011

BIO issues statement commending today’s ruling by the U.S. Supreme Court in ...

February 14 2011

Biotechnology Industry Organization (BIO) Industry Analysis and  BioMedTracker (BMT)...

February 9 2011

BIO announces that former Senator John B. Breaux (D-LA), former Member, Senate Finance...

January 26 2011

BIO's commends President Obama for highlighting the need to increase our nation...

January 12 2011

Experts chosen to speak on these panels represent leading clinical institutions, medical...

January 6 2011

BIO releases a report by Health Advances on the limitations of the nation’s...

January 3 2011

The 2011 BIO International Convention will highlight the latest trends and the newest...

September 29 2010

BIO President and CEO Jim Greenwood released the following statement on action by the U.S....

August 24 2010

BIO President and CEO Jim Greenwood issued the following statement today regarding the...

May 4 2010

A new report issued by the Biotechnology Industry Organization underscores how biotechnology...

March 22 2010

Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood released the...

October 15 2009

The Biotechnology Industry Organization (BIO) today announced Plenary Session and Business...

March 9 2009

BIO lauded President Barack Obama’s Executive Order to allow the National Institutes of...

June 18 2008

BIO announced today the release of a paper outlining incentives to encourage innovation for...

September 21 2007

Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood released the...

September 19 2007

Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood released the...

April 12 2007

Jim Greenwood, President and CEO of the BIO, issued the following statement on S. 5, the Stem...

April 12 2007

S. 3 Would Weaken Medicare Part D Drug Benefit

April 10 2007

The widening use of new, innovative biopharmaceutical treatments for diseases, such as cancer,...

February 26 2007

Private Sector Negotiations for Medicare Part D Provide Savings and Access to Innovative...

January 11 2007

The recommended improvements to the Prescription Drug User Fee Act (PDUFA) announced today by...

November 25 2003

Carl B. Feldbaum, president of the Biotechnology Industry Organization (BIO), today issued the...

May 22 2002

The House of Representatives today voted 425-1 to approve “The Public Health Security...

June 30 1999

 The American Hospital Association and BIO have signed a memorandum of understanding to...

November 12 1998

Carl B Feldbaum, president of  BIO, today issued the following statement on the need for...

July 22 1998

BIO is not surprised to learn that the Roslin Institute has verified the origins of Dolly the...

February 11 1998

Carl B. Feldbaum, president of BIO today issued the following statement after the Senate voted...

January 7 1998

Carl B. Feldbaum, president of BIO, today issued the following statement in response to news...

June 7 1997

Carl B. Feldbaum, president of BIO, issued the following statement today in response to the...

Letters, Testimony & Comments

April 17 2016
BIO member companies are committed to improving human health through the development of innovative therapies. We strongly support research that aims to improve human health through better drug development and recognize that responsibly sharing our clinical trial data can help to advance such research, while reinforcing public confidence in the safety and efficacy of our medicines.
April 4 2016
The Biotechnology Innovation Organization (BIO) is pleased to submit comments in response to the Centers for Medicare & Medicaid Services’ (CMS’s) Final Rule with Comment entitled Medicaid Program; Covered Outpatient Drugs Final Rule with Comment Period (the “FC”).1 As directed by the Agency, the scope of our comments is limited to the single topic open for public comment: “The definition and identification of line extension drugs.”2 
March 13 2016
BIO strongly supports efforts by the Agency, such as the Pilot COA Compendium and recent updates to the FDA’s drug development tool (DDT) qualification website, to promote the efficient development and use of COAs and other DDTs for drug development and regulatory decision-making. We believe that the COA Compendium is a good step in providing information to the public about COAs in development and use, providing a level of transparency and increasing awareness of efforts towards patient-focused drug development and COA information.
February 16 2016
BIO supports FDA’s assertion that “it is critical for sponsors to detect and report, as early as possible, serious and unexpected suspected adverse reactions and clinically important increased rates of previously recognized serious adverse reactions,” and we appreciate the publication of this Draft Guidance to aid Sponsors in this responsibility. However, we are concerned about the prescriptive nature of this Draft Guidance and its emphasis on the Safety Assessment Committee (SAC). We are also concerned that FDA may not fully appreciate the time and resources required of Sponsors to implement the recommendations within the Draft Guidance.
February 8 2016
BIO strongly supports the Prescription Drug User Fee Act (PDUFA 5) program to enhance FDA-Sponsor communication, which is based on FDA’s stated philosophy that “timely interactive communication with Sponsors during drug development is a core activity to help achieve our mission to facilitate the conduct of efficient and effective drug development programs, which can enhance public health by making new safe and effective drugs available to the American public in a timely manner.” BIO applauds FDA’s effort to give IND Sponsors and FDA review staff best practices and procedures for timely, transparent, and effective communications during drug development through this Draft Guidance.

Press Releases

April 25 2016
Washington, D.C. (April 25, 2016) – The Biotechnology Innovation Organization (BIO) issued the following statement today regarding the Campaign for Sustainable Rx Pricing’s policy proposals on prescription drug prices:
April 6 2016
Washington, D.C. (April 6, 2016) – Biotechnology Innovation Organization (BIO) President and CEO Jim Greenwood released the following statement regarding today’s Senate HELP Committee mark-up of legislation as part of the Senate biomedical innovation initiative:
March 30 2016
Washington, D.C. (March 30, 2016) – Biotechnology Innovation Organization (BIO) President and CEO Jim Greenwood issued the following statement today regarding the American College of Physicians’ policy paper on prescription drugs:
March 17 2016
Washington, D.C. (March 17, 2016) – Biotechnology Innovation Organization (BIO) President and CEO Jim Greenwood released the following statement regarding the introduction today by Senators Alexander and Murray of the FDA and NIH Workforce Authorities Modernization Act: